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Abstract
Receptor Tyrosine Kinases (RTKs) and Focal Adhesion Kinase (FAK) regulate multiple signalling pathways, including
mitogen-activated protein (MAP) kinase pathway. FAK interacts with several RTKs but little is known about how FAK
regulates their downstream signalling. Here we investigated how FAK regulates signalling resulting from the overexpression
of the RTKs RET and EGFR. FAK suppressed RTKs signalling in Drosophila melanogaster epithelia by impairing MAPK
pathway. This regulation was also observed in MDA-MB-231 human breast cancer cells, suggesting it is a conserved
phenomenon in humans. Mechanistically, FAK reduced receptor recycling into the plasma membrane, which resulted in
lower MAPK activation. Conversely, increasing the membrane pool of the receptor increased MAPK pathway signalling. FAK
is widely considered as a therapeutic target in cancer biology; however, it also has tumour suppressor properties in some
contexts. Therefore, the FAK-mediated negative regulation of RTK/MAPK signalling described here may have potential
implications in the designing of therapy strategies for RTK-driven tumours.
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Introduction
Research in model organisms can provide important insights on
the effects of oncogenic pathways in different in vivo environments
[1,2]. Particularly, Drosophila melanogaster has made numerous
contributions to cancer biology, e.g. by identifying components of
several signalling pathways such as the Hippo [3] and RTK/Ras/
MAPK signalling pathways [4–7].
FAK is a cytoplasmic non-receptor tyrosine kinase that interacts
primarily with Integrins at the focal adhesion sub-domains of the
plasma membrane (reviewed in [8]). FAK belongs to a hub where
phosphorylation signals are regulated and transferred into the cell,
therefore it is implicated in many cellular processes such as
adhesion, migration, survival and differentiation [8,9], and is
normally found over-expressed in migrating and invasive tumour
cells [10]. The current knowledge suggests that abnormal FAK
activation is a key driver of tumour cell motility and survival in
conditions that would trigger anoikis (detachment-dependent
apoptosis) (reviewed in [10,11]). Thus, FAK has been regarded
as a potential target for cancer therapeutics.
In Drosophila, there is a single FAK homologue (FAK56D, here
aftercalled dFAK [12–14]); dFAK is ubiquitously expressed, with
particularly high levels in the developing Central Nervous System
(CNS) and muscle [14]. Consistently, dFAK mutants have
abnormal neuromuscular junction growth and optic stalk structure
[15,16]. Nevertheless, dFAK mutants are viable and fertile [17],
proving it is dispensable for general development. This suggests
the role of dFAK may become apparent only under conditions of
stress. In fact, dFAK mutants display sensitivity to mechanical
stimuli, suffering seizure and temporal paralysis [18].
As oncogene activation is a condition of stress, we examined the
role of dFAK within a context of a Drosophila model of cancer [19–
21] achieved by the expression of the receptor tyrosine kinase
RET (Rearranged during transformation). Activating mutations in
RET cause the familial cancer syndrome Multiple Endocrine
Neoplasia type 2 (MEN2) (reviewed in [22,23]). Furthermore,
chromosomal translocations implicating ectopic expression of
RET are frequent in Papillary thyroid Carcinoma (PTC), the
most common type of thyroid cancer [24,25], pheochromocyto-
mas [26] and breast carcinoma [27].
Several RTKs were described to directly phosphorylate and
activate FAK [28,29]. Interestingly, direct interaction and mutual
phosphorylation between FAK and RET has also been reported
[30,31]. Nevertheless, the functional importance of FAK in RTK
signalling in vivo, particularly in the context of tumour develop-
ment, is not yet clear [29] (reviewed in [11]). Therefore, dFAK is a
likely candidate to be activated by Drosophila RET (here after called
dRET) and mediate its signalling cascade in Drosophila.
In this study, we investigated the regulatory role of FAK
downstream of RTKs in epithelial tissues. Unexpectedly, our
findings demonstrate that FAK constitutes a negative regulator of
RET and also, the RTK epithelial growth factor receptor (EGFR).
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FAK impairs RTK signalling specifically via the Ras/MAPK
pathway, which in turn impacts on the survival and differentiation
outcomes of RTK-expressing tissues. Because FAK is currently
considered an oncogenic target, our study may have implications
in future cancer therapies. Our results suggest that targeting FAK
in the context of some RTK-driven tumours might be detrimental
rather than beneficial for the host.
Results
RET activates FAK and MAPK
We expressed a constitutively activated form of dRET (hereafter
called dRETCA) with the ptc-gal4 driver, which is active in a stripe
of cells immediately anterior to the Anterior/Posterior compart-
mental boundary of the developing wing imaginal discs (Figure 1A
and 1D). GFP expression by itself did not affect this cell population
nor produced activation of the cytoplasmic kinases Src, FAK or
MAPK (Figure 1A–C). As expected from previous studies [19],
expression of dRETCA (ptc.dRETCA) led to phosphorylation of Src
and MAPK on residues that report their activation (Figure 1D–E,
see methods). Interestingly, we also observed increased phosphor-
ylation of FAK (Figure 1F).
Next, we tested genetically the importance of Src, Ras/MAPK
and FAK downstream of RET. The Drosophila compound eye is an
elegant structure composed of about 750 hexagonal units called
ommatidia, which pattern in a honeycomb-shaped array
(Figure 1G) [32]. This repetitive array makes the eye very sensitive
to perturbations in signalling pathways. The ectopic expression of
a single wild type copy of the Drosophila RET gene (hereafter called
dRETWT) under the direct control of the eye-specific GMR
promoter (GMR-dRETWT) disturbed the normal array of omma-
tidia, creating a ‘rough’ eye phenotype (Figure 1H; [19]). In a
search of genes involved in dRET signalling, previously known
members of the Ras/MAPK and Src signalling pathways were
identified (drk (Grb2), Sos, Ras85D, ksr, Gap1 (RasGAP), Src42A,
Src64B, Jra (c-Jun) and basket (JNK) [19]. As expected, we observed
that the dRET-induced phenotype was suppressed when Src42A
or Ras85D proteins were knocked down by RNA interference
(Figure S2A), confirming that they play key roles downstream of
dRET signalling.
Eyes from dFAKCG1 null mutants displayed normal patterning
(Figure 1L). Interestingly, and contrary to expectations of a
potential dRET-signalling effector, loss of FAK did not suppress
the rough eye phenotype. In fact, hetero- and homozygosis of
dFAKCG1 either enhanced the miss-patterning or caused a smaller
eye due to a completely disrupted ommatidial pattern, respectively
(Figure 1I and 1J).
To prove that only the loss of dFAK was responsible for the
phenotype observed in dFAKCG1; GMR-dRETWT animals (Figure 1J)
and no other genetic background mutation was influencing the
results, we next used two additional dFAK mutant strains (Figure
S1A). These strains bear a P-element insertion within dFAK and by
measuring the expression levels of dFAK mRNA transcripts were
confirmed to be hypomorphic lines (Figure S1B). Different dFAK
allelic combinations showed a similar genetic interaction with
GMR-dRETWT (Figures S1C).
The latter phenotype was comparable to the effect mediated by
high expression of dRETCA in the eye (Figure 1O). dFAK
overexpression rescued the effects of dFAK null mutation
(Figure 1K) and partially restored the small size induced by the
constitutively active RET isoform (compare Figure 1O with 1P;
eye sizes are quantified in S1D).
Overall, these data suggest that dRET activates dFAK, which in
turn may have unanticipated suppressive effects on RET
signalling.
FAK suppresses RET in different fly epithelia
To further test whether FAK can inhibit RET signalling we
combined dRET and dFAK in different imaginal discs using the
GMR-gal4, dpp-gal4 and ptc-gal4 drivers. dFAK overexpression by
itself had no apparent phenotype on adult survival and tissue
patterning (Figure 2A, B, E, F, I, J, M).
However, dRET expression did affect several tissues of the adult
fly. As mentioned above, dRETWT expression in the eye altered
the normal pattern of ommatidia (Figure 2C, see also 1H), which
was prevented when dFAK was simultaneously expressed
(Figure 2D). All escaper ptc.dRETCA adults showed wing vein
defects [33], with absence of the anterior cross vein, which lies
within the ptc domain of the wing anlage (Figure 2G). Remarkably,
this phenotype was rescued by the co-expression of dFAK and
dRETCA (Figure 2H). All escaper ptc.dRETCA adult males also
displayed rotation defects in the epandrium (Figure 2K). The
patched gene is expressed in a compartment-specific manner across
most imaginal discs in the larva, including the genital disc [34].
Therefore, dRET expression in this tissue perturbed normal
development and rotation of the male genital organ of adult
escapers [35,36]. Importantly, dFAK also suppressed this dRET-
induced phenotype and restored the proper orientation of the
male genitalia (Figure 2L).
Additionally, dRET expression also resulted in developmental
toxicity (with a penetrance that depended on the temperature and
other factors [33]). Correspondingly, 46% of ptc.dRETCA-
expressing flies made it to adulthood (n= 187) in our experimental
conditions. Co-expression of dRETCA and dFAK increased
survival up to 92% (n= 106) (Figure 2M). Conversely, loss of
dFAK enhanced the morphological defects induced by dRET in
the imaginal discs (Figure 2O–R) and reduced the survival rate of
dpp.dRETCA animals (Figure 2N).
Together, these observations demonstrate that dFAK inhibits
dRET-induced phenotypic effects in multiple imaginal disc
epithelia.
The N-terminal domain of FAK, but not its kinase activity,
is required to suppress RET
To gain insight into the mechanism by which FAK suppresses
RET signalling, we co-expressed dRETCA and different dFAK
mutant isoforms in the eye (schematised in Figure 3A). When
Author Summary
Due to their deregulation in cancer and their potential to
be inhibited by small chemical compounds, tyrosine
kinases are among the most important targets under
consideration for cancer therapeutics. One such oncogenic
tyrosine kinase is FAK, which is known to regulate cellular
signalling downstream of Integrins and Receptor Tyrosine
Kinases (RTK) at the cell surface. In this study, however, we
report that FAK can act as a suppressor of oncogenic
Receptor Tyrosine Kinases. This mechanism was observed
in fruit fly tissues in vivo and human cancer-derived cells in
vitro, which additionally suggests it is an evolutionary
conserved mechanism in humans. FAK mediated this
inhibition by controlling the sub-cellular localisation of
receptors, via suppression of receptor recycling to the cell
surface. These results suggest that in some particular
cancer contexts such as RTK-driven tumours, FAK may act
as a tumour suppressor and therefore, may not be a valid
drug target.
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Figure 1. Genetic interactions between RET and FAK. (A–F) Confocal images of wing disc epithelia. Control tissues (A–C) and experimental
tissues (D–F) expressed GFP driven by ptc-gal4, shown in A9 and D9. Experimental tissues (D–F) also expressed dRETCA. Immunostaining against pSrc
(A0 and D0), pMAPK (B and E) and pFAK proteins (C and F; see methods), as a proxy for probing their activation levels, are shown in grayscale panels.
Note increased phosphorylation of Src, MAPK and FAK after dRETCA expression within the ptc domain, indicated by red arrows. Scale bars, 50 mm. (G–
P) Images of adult eyes with indicated relevant genotypes; full genotypes are listed in supplemental material. GMR (glass multimer reporter) is an eye
specific promoter. GMR-gal4 was used to drive UAS-dFAK transgene expression. GMR-dRETWT and GMR-dRETCA are fusion recombinant constructs. Wild
type (G) and dFAKCG1 (L) animals displayed a normal eye pattern; note that the dFAKCG1 is in a white background (see Figure S1B). Expression of dRETWT
caused a mild eye miss-patterning phenotype (H), and lowering the genetic dose of dFAK gene in these animals either enhanced eye roughness (I–J)
or completely disrupted patterning and decreased eye size (J). Reciprocally, suppression of both effects was observed by co-expression of dFAK (K).
(M–N) A similar enhancement was observed by halving the dose of dFAK gene after expression of dRETCA. (O) Doubling dRETCA dose caused a very
rough and small eye, comparable to (J), which was partially suppressed when dFAK was also expressed (P). Eye size quantifications of panels G, H, J, K,
O and P are shown in Figure S1D. Scale bars, 100 mm.
doi:10.1371/journal.pgen.1004262.g001
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Figure 2. FAK suppresses RET-driven effects in different fly tissues. (A–D) Eyes expressing dFAK displayed a normal adult eye phenotype,
while dRETWT expression perturbed the normal pattern. Co-expression of dRETWT and dFAK supressed dRET-driven mis-patterning defects. Scale bar,
100 mm. (E–H) dFAK-expressing wings via ptc-gal4 showed no detectable defects similarly to control wings. Expression of dRETCA led to
disappearance of anterior cross veins in all adult escapers (arrow in inset box), which was rescued by simultaneous expression of dFAK with full
genetic penetrance. Scale bar, 500 mm. (I–L) ptc-driven dRETCA expression also led to incomplete rotation of the male genitalia in all adult escapers
(arrows). dFAK co-expression rescued this phenotype with full penetrance and it did not affect the normal development of the genitalia by itself.
Scale bar, 100 mm. (M) Quantification of the penetrance of adult eclosion for the indicated genotypes, note that dFAK co-expression rescued
significantly the developmental lethality of ptc.dRETCA animals. Error bars are standard deviation in this and all plots; ‘ns’ stands for non-statistically
significant, **** means p,0.0001 in this and all plots (see methods). (N) Conversely, dFAK loss, which by itself had no effect in viability, enhanced to
almost full penetrance the developmental lethality of dpp.dRETCA animals. (O–R) Confocal images from wing discs with the indicated genotypes.
Note that dFAK mutation enhanced the size and shape defects associated with ectopic expression of dRETCA within the dpp stripe. For a detailed
characterisation of the dFAK mutant alleles used here, please see Figure S1A–B. Scale bars, 50 mm.
doi:10.1371/journal.pgen.1004262.g002
FAK Inhibits RTK Signalling
PLOS Genetics | www.plosgenetics.org 4 March 2014 | Volume 10 | Issue 3 | e1004262
driven by GMR-gal4, the transcript levels from these UAS-dFAK
transgenes ranged from 20- to 40-fold over the endogenous levels
of dFAK transcript (Figure 3B). When expressed simultaneously
with dRETCA and by measuring the eye areas of the consequent
phenotypes (Figure 3C) we observed that a wild type allele of
dFAK significantly restored the eye size when compared to control
GMR.dRETCA eyes (Figure 3D and 3E). Interestingly, and in
correlation with observations made in different systems [30,31],
the N-terminal FERM domain of dFAK appears important for
this functional interaction between dFAK and dRET: expression
Figure 3. Requirement of the N-terminal FAK FERM domain. (A) Linear representation of dFAKmRNA, its derivatives UAS-transgenes and their
resultant protein isoforms: a full-length dFAK isoform; an N-terminal deletion mutant that lacks the first 400 amino acids residues of dFAK including
its FERM domain; and a point mutant isoform that bears a replacement of the Tyrosine430 residue for a Phenylalanine residue, which impairs the auto-
phosphorylation site and consequently the kinase activity of dFAK. (B) Expression profiles of each UAS-dFAK transgene in the eye (driven by GMR-gal4)
as determined by quantitative (q) PCR of RNA samples (see methods). We used a pair of primers (3F and 3L) flanking a 200 bp region corresponding
to the C-terminal domain (FAT: Focal adhesion targeting domain), which is a common region to all the isoforms. (C) Eye size quantification of the
indicated genotypes, shown in D-G. Eye sizes on the Y-axis are represented as relative values to the mean of GMR.dRETCA (‘ns’: not statistically
significant; **** = p,0.0001; n = 8–10 for each genotype). (D–G) Eye micrographs correspond to the indicated genotypes. Note that while the auto-
phosphorylation mutant version of dFAK was expressed at lower levels than the N-terminal mutant isoform (B), it was still able to rescue the size of
dRETCA-expressing eyes (G), to a similar extent as the full-length dFAK isoform (E). However, the N-terminal deletion mutant isoform did not suppress
the small eye size of dRETCA animals (C, D and F). Scale bar, 100 mm.
doi:10.1371/journal.pgen.1004262.g003
FAK Inhibits RTK Signalling
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of a N-terminal deletion mutant (dFAKDN) failed to modify the eye
size of GMR.dRETCA flies (Figure 3C and 3F). On the other hand,
a point mutant isoform in dFAK major auto-phosphorylation site
(FAKY430F, equivalent to tyrosine Y-397 in human FAK), did
significantly rescue the eye size of GMR.dRETCA flies and the
patterning of FAKCG1/+; GMR.dRETWT eyes (Figure 3G and
S2C). These results suggest that the FERM domain of dFAK is
necessary to inhibit RET signalling, while the major autophos-
phorylation site— required for full FAK kinase activity [37]—
may not be essential. Some systems require FAK as a scaffold
protein but not as a kinase [38] and our results suggest that this is
the case in the functional interaction with RET.
Moderate RET/FAK ratios suppress apoptosis
Next, we further characterized the RET/FAK regulatory loop
and its signalling output; specifically, we analysed how different
experimental conditions that altered relative RET/FAK levels
affected eye patterning. To gain further insights on how different
RET/FAK ratios influence tissue cell fate in vivo, we examined the
cell composition of the eye tissue. Each ommatidial unit consists of
eight photoreceptor and six supporting cells (four cone cells and
two primary pigment cells) (Figure 4A) [32] while a hexagonal
lattice of secondary and tertiary pigment cells surrounds the units
(white coloured in Figure 4A9–C9). Photoreceptor cell clusters are
specified first; they constitute ‘organizing centres’ that instruct
neighbouring cells to differentiate into cone cells and primary
pigment cells. The hexagonal lattice patterns by local cell
reorganization and elimination of surplus cells via a wave of
developmental programmed cell death.
We visualized the final pattern of retinas at 42 hs after
puparium formation (APF). dFAK mutant retinas were indistin-
guishable from their wild type counterparts (Figure 4A and 4B).
When dRETWT was expressed by itself, the ommatidial cores
remained normal, with four cone cells surrounded by two primary
pigment cells. Nevertheless, eye patterning was altered, displaying
supernumerary interommatidial cells (Figure 4C). This suggested
that developmental programmed cell death might be suppressed
during eye development. Indeed, while wild type or FAKCG1 retinas
displayed a large number of apoptotic cells at 28 h APF —a time
of high levels of developmental apoptotic cell death— there were
virtually no apoptotic cells in GMR-dRETWT retinas (Figures 4D–
F). Remarkably, developmental cell death was rescued by co-
expression of dRETWT and dFAK, further demonstrating the
ability of dFAK to suppress dRET signalling (Figure 4G).
Programmed cell death during eye development is mainly
dependent on the pro-apoptotic protein Hid (Head Involution
Defective) [39–41]. Hid over-expression in the developing eye
(GMR-hid) triggers apoptotic cell death throughout the tissue
leading to a small eye phenotype (Figure 4H) [42]. When
dRETWT was simultaneously expressed with Hid, the eye size
increased significantly (Figure 4J and 4L), indicating that RET
signalling could block Hid or its downstream effectors. The ability
of dRET to suppress Hid-induced apoptosis depended on its
known effectors Src and Ras: down-regulation of Ras85D or
Src42A by RNA interference prevented dRET-mediated suppres-
sion of GMR-hid small eye phenotype (Figure S2B). In contrast,
while dFAK expression by itself had no significant effects on the
GMR-hid eye phenotype (Figure 4I), it did suppress dRET
inhibitory effect (Figure 4K and 4L).
Taken together, our data suggest that dRET expression
suppresses both ectopic (Hid-induced) and developmental cell death
via its known effectors Src and Ras, and this effect can be suppressed
by dFAK co-expression. Therefore, in the retina, the output of
dRET overexpression in a dFAK wild type background—genetically
defined here as a moderate RET/FAK ratio and expected to
produce a moderate level of Ras/MAPK signalling— is the
inhibition of cell death.
High RET/FAK ratios drive ectopic differentiation
While the output of moderate RET/FAK ratios resulted in
suppression of cell death, the small eye phenotypes observed under
conditions of higher RET/FAK ratios suggested different cell fate
outcomes. We then further analysed two different experimental
conditions expected to produce high relative levels between RET
and FAK, namely (i) the expression of one copy of dRETWT in a
dFAK mutant background (dFAKCG1; GMR-dRETWT), and (ii) the
expression of two copies of dRETCA in a dFAK wild type
background (2X GMR-dRETCA), as these displayed the roughest,
reduced eye size phenotypes (Figure 5B and 5C, see also Figure 1J
and O). dFAKCG1; GMR-dRETWT pupal retinas lacked the
hexagonal array and identifiable ommatidial units (Figure 5F–
F9). In this case, there were clusters of numerous cone-like cells.
Some bristle cells and a few cells recognisable as primary pigment-
like remained, but there were no detectable cells with the
appearance of normal interommatidial cells (Figure 5F9). In order
to confirm the identity of those cells, we stained for the
transcription factor Cut, a well-known cone cell marker [43]. In
control retinas, Cut localised constitutively to the nucleus of the
four cone cells from each ommatidium (Figure 5E0) [43]. In
contrast, in dFAKCG1; GMR-dRETWT retinas (Figure 5F0), the cell
clusters were indeed made of numerous Cut-expressing cone-like
cells. Thus, in these experimental conditions, dRET signalling
drives ectopic differentiation into the cone cell fate.
We next tested whether the supernumerary cone cells could be a
consequence of ectopic differentiation during the larval stage.
Since photoreceptor cells induce cone cell differentiation, one
possibility is that aberrant photoreceptor cell numbers trigger
ectopic cone cell differentiation. We observed normal numbers of
photoreceptors (i.e.; clusters of eight) in dFAKCG1; GMR-dRETWT
eye discs, albeit some clusters had rotation defects (Figure S3A–C).
We also observe ommatidial units with extranumerary cone cells
at early stages of eye development (4 h APF; Figure S3E) that
suggests these ectopic clusters might accumulate during develop-
ment until a mesh of mostly cone cells is observed by 42 h APF.
Similarly, 2X GMR-dRETCA pupal retinas displayed a mesh of
cone-like cells as shown by Cut staining (Figure 5C and 5G–G0),
where the few remaining cells displayed bristle cell morphology.
The expression of dFAK within this context rescued the small eye
size phenotype (Figure 5D; quantified in S1D). Most remarkably,
it also reduced the number of ectopic cone cells and resulted in the
re-appearance of normal ommatidial cores and surrounding
interommatidial cells in the pupal retinas (Figure 5H–H0).
Moreover, the down-regulation of Ras85D also prevented this
ectopic differentiation, restoring the eye size and suppressing
patterning defects (Figure S3D).
Together, these results indicate that in a genetically defined high
RET/FAK ratio, expected to produce high Ras/MAPK signal-
ling, most of non-neuronal eye cell types ectopically differentiate
into cone cells.
FAK impairs MAPK signalling downstream of RET
Next, in order to gain insights into the mechanism of dRET
signalling inhibition, we assessed the role of dFAK in influencing
dRET-signalling effectors.
dRET was reported to activate the PI3K/Akt pathway [33],
therefore we assessed whether there was also an ectopic activation
of Drosophila Akt1 in our experimental conditions. Overexpression
of Drosophila Insulin receptor (dInR), an RTK known to signal
FAK Inhibits RTK Signalling
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Figure 4. Moderate relative RET/FAK levels lead to inhibition of programmed cell death. (A–C) Armadillo immunostaining revealed cell
outlines of wild type (A), dFAKCG1 (B), and GMR-dRETWT (C) retinas at 42 hs after puparium formation (APF). The boxed areas were traced to highlight
their cellular composition (A9–C9). Each ommatidium is composed of 4 cone cells (red), 2 primary pigments cells (yellow), 6 secondary and
three tertiary cells (white), and three-bristle cells (green) make the hexagonal lattice. Note that dFAKCG1 eyes display normal patterning (B9) while
FAK Inhibits RTK Signalling
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primarily via the PI3K/Akt pathway [44], resulted in increased
immunostaining for phosphorylated-Akt1 (pAkt) (Figure S4E and
S4G); nevertheless, that was not the case after expression of dRETCA
(Figure S4C and S4G). This suggests that dRET signals indepen-
dently of PI3K/Akt in the imaginal disc domains we utilized.
We showed above that Src and MAPK were activated upon
RET expression (Figure 1D–E). dFAK overexpression on its own
within the ptc domain of the wing disc also resulted in increased
levels of pSrc (Figure S4I). However, the co-expression of dRET
and dFAK did not affect notably the levels of pSrc (Figure S4K
and S4L). These results indicate that dFAK does not suppress
dRET signalling via Src.
Regarding MAPK, dFAK expression did not modulate MAPK
phosphorylation when expressed by itself (ptc.dFAK) (Figure 6B)
but did reduce MAPK phosphorylation within the dRETCA-
overexpressing ptc compartment of the wing disc (Figure 6C–E).
This indicates that dFAK is able to inhibit dRET signalling via the
MAPK pathway.
GMR-dRETWT retinas displayed normal ommatidial cores but additional interommatidial cells (white cells in C9). Scale bars, 10 mm. (D–G) TUNEL
labelling of retinas at 28 h APF. Note that the developmental programmed cell death observed in wild type and dFAKCG1 retinas were suppressed in
GMR-dRETWT retinas. Co-expression of dFAK rescued this inhibition of cell death (G). Scale bar, 50 mm. (H–K) Hid overexpression (GMR-hid) gave a
small eye phenotype, which was suppressed by dRETWT co-expression (J). This dRET-dependent inhibition was also suppressed by dFAK co-
expression (K) while dFAK itself did not suppress Hid-mediated effects in the eye (I). Scale bar, 100 mm. (L) Eye size quantification of the indicated
genotypes (as depicted in panels H–K) represented as relative values to the wild type mean value (‘ns’: not statistically significant; **** = p,0.0001;
n = 8–10 for each genotype).
doi:10.1371/journal.pgen.1004262.g004
Figure 5. High relative levels between RET and FAK induce ectopic cone cell differentiation in the eye. We examined the cellular
patterning of the pupal retinas in correspondence to the adult eye phenotypes shown in panels A–D. Scale bars, 100 mm. (E–H) Merged images of
stainings for nuclei (DAPI, blue), Dlg (cell outlines, red) and Cut (cone cells, green), from retinas at 42 h APF. Bottom panels show Dlg (E9–H9) and Cut
(E0–H0) immunostainings individually. (E) Note the symmetric hexagonal array, and four Cut+ cone cells per ommatidium (white arrows) in control
retinas. (F and G) Note the change in cellular composition of these retinas with high RET/FAK ratios, primarily composed of Cut+ cone-like cells. (H)
dFAK expression within a 2X GMR-dRETCA background suppressed this phenotype (also see S1D); some normal four-cone cell clusters (white arrows)
can be identified and interommatidial cells reappeared (yellow arrows). Scale bars, 10 mm.
doi:10.1371/journal.pgen.1004262.g005
FAK Inhibits RTK Signalling
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Interestingly, the eye phenotypes mediated by activated
isoforms of Ras and Raf, two components of the MAPK kinase
pathway, were not suppressed by dFAK co-expression (Figure S5),
suggesting that dFAK-mediated inhibition of dRET/MAPK
signalling occurs upstream of Ras.
FAK suppresses EGFR signalling
Next, we evaluated whether the ability of FAK to inhibit
RTK/MAPK signalling was specific to RET. The epithelial
growth factor receptor (EGFR) is known to bind to FAK in
mammals [29,45] and to activate MAPK in Drosophila [46].
Therefore, we took a similar approach and co-expressed the
dEGFR with dFAK in the eye or in the ptc domains through the
GMR-gal4 and ptc-gal4 drivers, respectively. As it happened with
dRET, dEGFR also induced dFAK (Figure S6A) but not Akt1
activation (Figure S6B–B9). Co-expression with dFAK resulted in
a significant rescue of the GMR.dEGFR phenotype (Figure 7A
and 7B) and inhibition of MAPK activation (Figure 7C–E).
Moreover, dFAK allowed a remarkable increase in survival of
ptc.dEGFR flies (Figure 7F).
Mechanistically, dFAK seems to act in a similar fashion with
both RTKs as the mutant isoforms of dFAK showed the same
pattern of suppression when co-expressed within a GMR.dEGFR
context: the auto-phosphorylation mutant was still capable of
rescuing (Figure S6F), while the amino-terminal domain mutant
failed to modify the phenotype of dEGFR overexpression (Figure
Figure 6. FAK inhibits RTK signalling by impairing Ras/MAPK pathway. (A–D) Phosphorylated (active) MAPK immunostainings from wing
discs with the indicated genotypes. (A–B) When dFAK was expressed in the ptc-compartment (green), pMAPK staining was unchanged compared to
GFP-only expressing cells. (C–D) dRETCA expression increased pMAPK staining in the ptc domain but co-expression with dFAK suppressed this dRETCA-
induced activation of MAPK. Scale bars, 50 mm. (E) Quantification of pMAPK immunostaining within the ptc stripe (see methods). Intensity of pMAPK
signal is represented as relative values to the mean intensity of control tissues (A) (‘ns’: not statistically significant; **** = p,0.0001; n = 4–6 for each
genotype).
doi:10.1371/journal.pgen.1004262.g006
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S6E). Thus, the FERM domain of dFAK appears essential to
initiate the negative regulation over RTKs.
This implies that dFAK not only suppressed dRET but can also
suppress other RTKs, namely dEGFR.
Phylogenetic conservation role for FAK downstream of
RTK signalling
We next tested whether the negative role of FAK downstream of
RTK signalling was evolutionary conserved. Since FAK inhibited
Figure 7. FAK suppression of RTK signalling is conserved. (A–B) Adult eyes images of animals expressing Drosophila EGFR (dEGFR) alone or in
combination with dFAK. Note that dFAK expression suppressed the rough, small eye phenotype driven by dEGFR. Scale bar, 100 mm. (C–C9)
Expression of dEGFR within the ptc domain resulted in increased MAPK phosphorylation, and co-expression of dFAK rescued the ectopic pMAPK
staining within the ptc stripe (D–D9). Scale bar, 50 mm. (E) Quantification of pMAPK immunostaining within the ptc stripe (see methods). Intensity of
pMAPK signal is represented as relative values to the mean intensity of control tissues (Figure 6A; **** = p,0.0001; n = 4–6 for each genotype). (F)
Quantification of the penetrance on adult eclosion for the indicated genotypes. Note that dFAK co-expression significantly rescued the
developmental lethality associated to ptc-driven dEGFR expression (* = p,0.05). (G) Western blots from protein extracts from MDA-MB-231 cells after
48 or 72 h transfection with FAK siRNA. FAK protein levels were effectively knocked down. While total levels of EGFR and ERK were not changed at
48 h, there was a marked upregulation in phosphorylated ERK1/2 upon FAK knockdown, which was more apparent at 48 h after siRNA transfection.
Actin levels were probed as an additional loading control. (H) MDA-MB-231 cells were transfected with either non-targeting (siNT) or FAK-specific
siRNA (siFAK) and serum starved prior to addition of EGF. Note that FAK knockdown resulted in increased phosphorylation of ERK1/2 in response to
EGF treatment (30 mM, 15 minutes).
doi:10.1371/journal.pgen.1004262.g007
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dEGFR signalling, we utilized MDA-MB-231 cells, derived from a
human breast adenocarcinoma, which express high levels of
EGFR and FAK [47–50]. An efficient knockdown of the FAK
protein was achieved using small interfering RNAs by 48 hours
after transfection (Figure 7G and S7A). Remarkably, when cells
were grown in presence of serum we observed an increase of
ERK1/2 (MAPK) phosphorylation (pERK1/2) after FAK knock-
down, while the total ERK1/2 and EGFR levels remained
constant. ERK1/2 phosphorylation levels were also increased at
72 hs after transfection but at this later time point EGFR levels
were mildly upregulated (Figure 7G and S7A).
When serum-starved FAK-siRNA MDA-MB-231 cells were
treated with EGF in order to selectively stimulate EGFR receptor,
the same dramatic increase of ERK (MAPK) activation was
observed (Figure 7H and S7B). These results indicate that the
suppressive role of FAK on RTK/MAPK signalling is evolution-
ary conserved through EGF/EGFR signalling in human breast
cancer cells.
FAK reduces the fraction of EGFR located at the cell
surface
To gain mechanistic insights into how FAK suppresses RTK/
MAPK signalling, we next examined the cellular distribution of
EGFR in MDA-MB-231 cells. Previous work indicated that
growth factor receptors regulate cell signalling differently depend-
ing on its localization at the plasma membrane or within
internalized vesicles [51–53]. In most contexts, EGFR signals to
MAPK preferentially when located at the cell surface [54,55].
Since knockdown of FAK at 48 h did not affect total levels of
EGFR, we hypothesised that a change of receptor subcellular
localization could explain the enhanced ERK signalling.
To assess whether FAK affects receptor subcellular localization,
we performed immunofluorescence stainings for EGFR in control
and FAK knockdown cells (Figure 8A and 8B). A 27% increase in
the fraction of total EGFR located at the plasma membrane was
observed in siFAK-treated cells, at the expense of the intracellular
pool (Figure 8C). This suggested that the increase of EGFR at the
cell surface could account for the increased ERK signalling in cells
with reduced FAK levels. To further test this hypothesis, we
experimentally increased the fraction of EGFR at the plasma
membrane using the Dynamin GTPase inhibitor Dynasore, widely
used to retain receptors at the cell surface [56–59]. This treatment
phenocopied FAK knockdown as it led to increased pERK1/2
levels without affecting ERK1/2 or EGFR total levels (Figure 8D
and S8).
Taken together, these results indicate that FAK disfavours
localisation of EGFR at the plasma membrane thus reducing
receptor signalling into the MAPK pathway.
FAK reduces EGFR recycling to the cell surface
Finally, we asked how FAK might affect the receptor sub-
cellular localisation. Receptors are normally internalised into the
endosomal/lysosomal compartment, when they can be either
degraded or spared from degradation and returned to the cell
surface [60].
We performed pulse-chase biochemical assays [61] to quantify
the rates of EGFR internalisation and recycling. We did not detect
significant differences in the rate of EGFR internalization
(Figure 8E). Instead, the recycling of the internal EGFR pool
was significantly higher (36%) in cells with reduced FAK versus
control cells (Figure 8E). These results correlate with the
percentages of membrane EGFR observed in Figure 8A–C and
hence indicate that FAK suppresses EGFR localisation at the
plasma membrane by suppressing receptor recycling but not
internalization.
Discussion
This study provides evidence that RTK signalling can be
moderated by FAK through the regulation of RTK recycling. This
mechanism appears specific for the case of RTK over-expression/
hyper-activation. We found that ectopic dRET and dEGFR
signalling were able to activate dFAK and the MAPK pathway.
Nevertheless, dFAK negatively regulated RTK-induced signalling
to the MAPK pathway. The highly conserved FERM domain of
dFAK appeared necessary for its functional suppression of
Drosophila RTK signalling, which is consistent with the physical
interactions of FAK and several RTKs described in mammals
[28,30,62]. This negative feedback regulation indicates that the
balance between RTK and FAK is what determines the intensity
of MAPK pathway activity, which ultimately dictates cellular fate
(Figure 8F).
We characterized cell fate outcomes in detail in the patterning
eye anlage. In this tissue, it is known that different thresholds of
MAPK pathway activation result in different outcomes: moderate
levels of activation promote survival of cells during the wave of
developmental apoptosis [63], while high levels of activation result
in ectopic differentiation into photoreceptors [63] or the cone cell
fate [64]. Correspondingly, we observed that experimental genetic
manipulations expected to produce moderate RET/FAK ratios —
such as the expression of one copy of wild type dRET in a dFAK
wild type background— resulted in reduced developmental
apoptosis and supernumerary interommatidial cells. On the other
hand, genetically defined high RET/FAK ratios —such as the
expression of one copy of wild type dRET in a dFAK mutant
background, or the expression of two copies of constitutively
activated dRET in a dFAK wild type background— resulted in
ectopic differentiation into cone cells. Importantly, all dRET-
driven phenotypes were suppressed by the co-overexpression of
dFAK, which lowered RET/FAK ratios.
The initial characterization of the dRET-driven eye model
identified several components of the Src and Ras/MAPK
pathways [19]. These authors further observed that high levels
of dRET signalling, achieved by the expression of two copies of
activated RET, resulted in non-patterned retinas composed of
identical cells with cuboidal morphology, which were proposed to
be undifferentiated precursor cells. This led to the conclusion that
high dRET signalling could block differentiation in this tissue. We
report here that under similar experimental conditions, such
cuboidal cells express the cone cell marker Cut. Thus, we conclude
that high relative levels between dRET and dFAK result in a
proportional activation of the MAPK pathway, which force
differentiation into the cone cell fate.
Previous work reported that in dFAK mutant embryos, the
activity of the MAPK pathway is normal during development [16].
This indicates that endogenous MAPK signalling does not
normally became hyper-activated simply as a result of dFAK loss
and is in sharp contrast to the case of over-expression of RET or
EGFR as reported here. We postulate that in imaginal disc
epithelia, dFAK constitutes a signalling ‘‘fuse’’ that can act in a
negative feedback loop over RET and other RTKs, specifically in
conditions of ectopic RTK activation or expression. Relevant to
this, we recently reported that mammalian FAK can protect
epithelial cells from deregulated RET or Src signalling; when FAK
is absent, some epithelial cancer cells specifically respond by
targeting these promiscuous oncogenic kinases for autophagic
degradation [31,65]. It therefore seems that a common feature of
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Figure 8. FAK decreases EGFR at the plasma membrane via reduced recycling. (A–B) MDA-MB-231 cells transfected with non-targeting (NT)
siRNA or FAK siRNA were immunostained with anti-EGFR antibody (green, A0 and B0), Rhodamine-phalloidin (red, A9 and B9) and DAPI (blue). Note the
differential localisation of EGFR; while in siNT cells the receptor is distributed in plasma membrane and internal vesicles, FAK downregulation leads to
an increase of EGFR levels at the cellular membrane. Scale bar, 10 mm. (C) Quantification of relative EGFR membrane levels, values are expressed as
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FAK regulatory function is to ‘buffer’ cells against potentially
hazardous tyrosine kinases-mediated oncogenic signalling by
promoting their internalization [31,65].
In Drosophila, negative regulation of MAPK by dFAK has been
previously observed in neuromuscular junction (NMJ) growth
[16]; in fact, this was one of the few developmental defects
detectable in dFAK mutant animals. Interestingly, it was suggested
that this ‘non-canonical’ negative regulation of MAPK by dFAK
was specific to the process of Integrin-dependent NMJ growth
[16]. Importantly, our data imply instead that this is a more
commonly used mechanism that occurs also in epithelial tissues,
downstream of ectopic dRET and dEGFR signalling. Thus, the
negative regulation of RTK/MAPK signalling by dFAK is more
widespread across Drosophila tissues, and we show that this has
important consequences for cell and tissue fate. Most importantly,
we observed that the ability dFAK to restrain signalling through
the MAPK pathway is evolutionary conserved in a human breast
carcinoma cell line downstream of EGFR signalling. We
demonstrate that this novel role of FAK relies on its ability to
affect receptor sub-cellular localisation. RTKs normally reside at
the plasma membrane or within internalised cytosolic vesicles.
There is a constant transport of vesicles between these two pools,
which allow cells to keep a healthy RTK signalling by degrading
old receptor molecules or resetting their activity and sending them
back to the cell surface. RTKs can activate a certain signalling
pathway either from the plasma membrane or endocytic vesicles;
here we showed that EGFR signals to Ras/MAPK pathway
preferentially from the cell surface, and FAK is able to regulate its
localisation by reducing recycling, while the internalization rates
are unaffected. Thus, in a context where MAPK signalling is
activated preferentially by the plasma membrane pool of EGFR
[51–53], an increase of receptor located at the cell surface results
in enhanced MAPK signalling.
We also present evidence that the N-terminal FERM domain of
dFAK may be essential in the regulation of RTKs, while its kinase
activity appears dispensable. These results highlighted the
important regulatory roles of the FERM domain, likely by
mediating interactions with RET and EGFR. Future studies
should elucidate how FAK, presumably acting as a scaffold
through its FERM domain, interacts with the recycling endosome
machinery to control RTK recycling.
The attenuation of the MAPK signal transduction pathway by
FAK is in stark contrast to the well-established role of FAK linking
integrin engagement to the activation of Ras/MAPK [66].
Therefore, the regulation of MAPK by FAK may be context-
dependent. It is worth noting that most previous studies reporting
the activation of MAPK by FAK utilized immortalized cultured
fibroblasts [66]; it is possible that FAK negative regulation of
MAPK applies to epithelial cells in situ and acts downstream of
RTKs but Integrins.
High expression or activation of FAK in a range of human
carcinomas [49] and its role promoting migration and survival of
malignant cells, make it an attractive therapeutic target. In fact,
many small molecule inhibitors have been developed to target
FAK kinase activity or its FERM domain, and clinical trials are in
progress [67] [68]. However, in some tumors FAK downregula-
tion has also been related with malignancy [69–72]. For instance,
in glioblastoma, a malignancy that is associated with EGFR
activation, there is an inverse correlation between pFAK and
pMAPK [73], as predicted in our model.
Therefore, the signaling crosstalk between FAK and RTK/
MAPK is complex and context-dependent [73], and a better
understanding of such roles of FAK will be useful as FAK
inhibitors move towards potential clinical use.
Materials and Methods
Drosophila stocks and culture
The following fly stocks were used: w1118 and Canton-S as a
wild-type reference; GMR-gal4 and sev-gal4 as expression drivers in
the eye [74]; patched (ptc)-gal4 and decapentaplegic (dpp)-gal4 as
expression drivers in a stripe of cells in the wing and genital discs
[34]; the dFAKCG1 mutant line, UAS-dFAK, UAS-dFAKDN and UAS-
dFAKY430F lines were made by R. Palmer [13,17]; GMR-dRETWT,
UAS-dRETC695R(MEN2A) and GMR-dRETC695R(MEN2A) were a gift
from R. Cagan (Mount Sinai Medical School, New York, USA)
[19]; dFAKKG00304, Ras85DRNAi, UAS-Ras85DV12, UAS-RafF179,
GMR-hid, and UAS-dInR lines were obtained from the Bloomington
Drosophila Stock Centre. Src42ARNAi line was obtained from the
Vienna Drosophila RNAi Centre. dFAK5-SZ-3124 was obtained
from the Drosophila Genetic Resource Centre. The UAS-dEGFR
line was obtained from Matthew Freeman [75]. All flies were
cultured at 25uC on standard molasses diet unless otherwise stated.
Please find in Text S1 the detailed genotypes of animals used in all
figures.
Overexpression using GAL4/UAS system
The GMR-gal4 line drives expression of UAS-linked transgenes
in differentiating and post-mitotic cells of the developing eye,
posterior to the morphogenetic furrow; the sevenless-gal4 line is
active in R7 photoreceptor cells; the patched-gal4 and decapentaplegic-
gal4 lines drive expression of UAS-linked transgenes within
compartments of cells in imaginal discs.
Immunofluorescence assays
Eye and wing imaginal discs or pupal retinas were dissected at
the indicated time points, in 1X PBS, fixed in 4% formaldehyde
for 30 minutes at room temperature, and rinsed in PBST (PBS,
0.1% Triton X-100). Tissues were incubated in primary antibody
at 4uC overnight. After PBST washing (3 times, 10 minutes each),
tissues were incubated for 2 hours in secondary antibody. Tissues
were rinsed in PBST and counterstained with DAPI (1 mg/ml,
SIGMA) for 5 min at RT and then mounted in Vectashield.
Primary antibodies used were anti-Armadillo (1:3, DSHB) and
relative levels of the receptor against the mean value of siNT cells; four confocal fields for each condition were analysed: n = 347 cells (siNT), and
n= 414 cells (siFAK). p,0.0286 in a Mann-Whitney test. (D) MDA-MB-231 cells were transfected with either non-targeting (siNT) or FAK-specific siRNA
(siFAK) and deprived of serum prior to addition of 80 mM Dynasore. siNT-transfected cells showed an increased pERK1/2 level in response to both
Dynasore treatment (80 mM, 30 minutes) and FAK knockdown. Total levels of EGFR and ERK were not changed and actin levels were probed as an
additional loading control. (E) The internalization of membrane EGFR (top panel) and recycling of internalised EGFR (bottom panel) were determined
in MDA-MB-231 cells transfected with non-targeting siRNA (siCTR) or FAK siRNA (siFAK). Values are means 6 Standard Deviation (SD) of two
independent experiments with four to eight replicates of each time point per genotype. See materials and methods for more details. FAK knockdown
did not affect receptor internalization but increased the recycling of the internalised EGFR pool. (F) A working model for the regulatory mechanism of
FAK. Ectopic expression and/or hyperactivation of RTKs activate FAK and Ras among other signalling pathways. FAK mediates a negative regulation
of receptor recycling; when FAK is reduced or absent, there are more RTKs molecules at the plasma membrane, thus enabling a higher flux of
signalling through Ras/MAPK pathway. See the text for more details.
doi:10.1371/journal.pgen.1004262.g008
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anti-Cut (1:50, DSHB), anti-phosphorylated (Y418)-Src (1:100,
Cell Signalling), anti-phosphorylated (Y397)-FAK (1:100, Cell
Signalling), anti-phosphorylated (T202/Y204)-MAPK (1:200, Cell
signalling), anti-Dlg (1:50, DSHB), anti-Prospero (1:30, DSHB),
anti-Elav (1:500, DSHB), anti-phosphorylated (S-473)-Akt1 (1:100,
Cell Signalling). Secondary antibodies were Alexa-conjugated 488,
594, or 633 (Molecular Probes). All preparations were analysed on
a Zeiss 710 upright confocal microscope and images were
processed with Fiji (ImageJ) program (NIH).
Quantification of immunofluorescence stainings
In order to quantify the intensity of immunostainings within the
ptc compartment of the wing discs, sum projections were created
from the original multi-slice files. Two identical areas were
defined, within the ptc domain (A1) and posterior to it (A2). The
‘mean grayscale value’ of each area was measured with Image J,
and the ratio between A1 and A2 was taken as the normalised
intensity of signal.
TUNEL (Terminal deoxynucleotidyl transferase (TdT)-
mediated dUTP Nick End Labelling)
Eye discs or retinas were dissected and fixed in 4% formalde-
hyde in PBT for 20 min at RT. Samples were permeabilized in
100 mM Sodium Citrate in PBST (PBS+0.1% Triton X-100) at
65uC for 30 min followed by the addition of TUNEL reagent
according to the manufacturer’s instructions (In Situ Cell Death
Detection Kit, Roche) and incubated at 37uC for 2 h on a rotating
platform.
Light microscopy
Adult eye and male genitalia images were taken with a Leica
M205 FA stereomicroscope equipped with Montage software.
Wing blades images were taken with an Olympus BX51 FL
Microscope.
RNA quantification
Total RNA was extracted from 10–15 heads or whole bodies
per biological replicate using RNeasy kit (Qiagen) and converted
into cDNA using the High-Capacity cDNA Reverse Transcription
Kit (Applied Biosystems). MAXIMA SYBR Green Master Mix
(Fermentas) was used for quantitative (q) PCR. Data from three
biological replicates were analyzed using Applied Biosystems 7500
software version 2.0 and GraphPad Prism 6 software. Data are
presented as the mean fold change relative to wild type with
standard deviations. Primers are listed in Text S1.
Statistical analysis
To statistically analyse eye size measurements, adult eclosion
and immunofluorescence signal we used Student’s unpaired t-test
to compare two groups of data or One-way ANOVA followed by
Bonferroni’s or Tukey’s post-test corrections to compare more
than two groups of data. Error bars are standard deviation in all
plots.
Cell culture and transfection
MDA-MB-231 cells were cultured in Dulbecco’s modified Eagle
medium (DMEM) supplemented with 2 mM glutamine and 10%
FBS (Fetal Bovine Serum) at 37uC in a humidified 5% CO2
atmosphere. siGENOME non-targeting (NT) siRNA pool (D-
001206-13-05) and Smartpool siRNAs targeting FAK (L-003164-
00) were obtained from Dharmacon, 10 ul of the 20 uM stock was
used in each transfection. Non-targeting and FAK siRNAs were
transfected into cells using Nucleofector Technology (Nucleofector
Solution V, program X-013; Lonza) and Nucleofector II, Amaxa
Biosystems.
Human cell imaging and analysis
MDA-MB-231 transfected cells were washed in ice cold PBS,
fixed in 4% paraformaldehyde for 10 minutes at room temper-
ature (RT), and permeabilised during 5 minutes in PBS+0.2%
Triton X-100. Then, cells were blocked in 1% BSA/PBS solution
for 30 minutes and incubated with primary antibody overnight.
Secondary antibody was added to cells for 1 hour at RT and then
cells were washed, incubated with FITC-Phalloidin for 10 minutes
and finally mounted in Vectashield with DAPI.
Imaging was done with an inverted confocal microscope
(FluoView FV1000; Olympus) with FluoView software (Olympus)
and processed with Fiji (ImageJ) software (National Institute of
Health). Immunofluorescence intensity values of EGFR were
obtained by creating a mask of the cell outline, defining a
threshold and measuring fluorescent intensity. Data analysis and
Mann-Whitney statistical tests were performed and plotted in
GraphPad Prism 6 software.
Western blotting
Assays were set up 48 or 72 hours after transfection. EGF
treatment (30 uM, 15 minutes - Millipore) was performed on
serum-starved cells, whereas all other experiments were conducted
in the presence of serum. Each assay was independently repeated
three times with similar results; the blots with the most equalized
loading as judged by b-actin labelling are shown.
Cells were washed in PBS (Phosphate buffered saline) and lysed
in lysis buffer (2% SDS, 100 mM Tris-HCl, pH 7.4). Cell protein
extracts were incubated at 95uC for 5 minutes, sonicated and
clarified by centrifugation at 10,000 g for 15 min. Protein
concentration was determined by Bradford method [76]. Proteins
were resolved by SDS-PAGE and analysed by Western blotting.
The following antibodies were used for immunoblotting: anti-b-
actin (1:10000, Abcam), anti-FAK (1:1000, C-20, Santa Cruz
Biotechnology), anti-phosphorylated (T202/Y204)-MAPK
(pERK1/2) (1:200, Cell signalling), anti-ERK1/2 (1:10000,
Promega), anti-EGFR (1:2000, BD Transduction Laboratories).
The Nitrocellulose membranes were incubated with secondary
antibodies IRDye 680RD anti-mouse (1:10000, LI-COR) and
IRDye 800CW anti-rabbit (1:10000, LI-COR) imaged with
Odyssey Imager (LI-COR Biosciences) and analysed with Image
Studio Lite software.
Receptor internalization and recycling assays
EGFR internalization and recycling assays were performed as
described previously for Integrins [61] [77], but without re-feeding
or serum-starvation. For internalization assays: MDA-MD-231
cells were transferred to ice, washed twice in cold PBS, and their
surface proteins labelled with 0.13 mg/ml NHS-SS-Biotin in PBS
at 4uC for 1 h. Labelled cells were washed in cold PBS and
transferred to serum-containing DMEM at 37uC for the indicated
times to allow internalization. After internalization, dishes were
rapidly transferred to ice and washed. Biotin remaining at cell
surface was removed by incubation with 20 mM MesNa (sodium
2-mercaptoethanesulphonate), 50 mM Tris pH 8.6, 100 mM
NaCl for 60 min at 4uC. MesNa was quenched by addition of
20 mM iodoacetamide for 20 min. Then, cells were washed and
lysed in 200 mM NaCl, 75 mM Tris, 15 mM NaF, 1.5 mM
Na3VO4, 7.5 mM EDTA, 7.5 mM EGTA, 1.5% Triton X-100,
0.75% IGEPAL CA-630, 50 mg/ml leupeptin, 50 mg/ml aproti-
nin, and 1 mM 4-(2-aminoethyl) benzynesulphonyl fluoride.
Lysates were clarified by centrifugation at 10,000 g for 10 min,
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and biotinylated EGFR was determined by ELISA. Briefly, 96-
well plates were coated overnight with monoclonal mouse anti–
EGFR (clone EGFR.1; BD Biosciences) at 5 mg/ml at 4Cu in
0.05 M Na2CO3 pH 9.6, and then blocked in PBS, 0.05% Tween
20, 5% BSA for 1 h at room temperature. EGF Receptors were
captured by overnight incubation of 50 ml cell lysate at 4uC. After
extensive washing with PBS-T to remove unbound material, wells
were incubated with streptavidin-conjugated horseradish peroxi-
dase for 1 h at 4uC. After further washing, biotinylated EGFR
molecules were detected by chromogenic reaction with orthophe-
nylenediamine.
For recycling assays, after surface labelling with Biotin, cells
were transferred to serum-containing DMEM and incubated at
37uC for 30 min to allow internalization. Then, cells were
returned to ice and washed in ice-cold PBS, and biotin was
removed from cell surface proteins by reduction with MesNa. The
internalized fraction was then chased by returning cells to 37uC in
serum-containing DMEM. After recycling, cells were returned to
ice, and biotin was removed from recycled proteins at the cell
surface by a second reduction with MesNa. Biotinylated EGFR
molecules were then determined by capture ELISA as described
above. Two independent recycling experiments were performed
with 4 to 8 independent measures of every time point and
genotype. Two-way ANOVA with Sidak’s multiple comparison
test was performed to obtain statistical significance between time
points.
Supporting Information
Figure S1 Different dFAK alleles enhance eye roughness caused
by dRET expression. (A) Adult eye images of the three dFAK
mutant lines used in this study. Normal ommatidia patterning was
observed. Scale bars, 100 mm. dFAKCG1 is an amorphic allele of
dFAK consisting of a deletion that removes the first 1263 base pairs
of the coding sequence, corresponding to the first 421 amino acids
of dFAK; please note this allele is in a white background [17]. (B)
dFAKKG00304 and dFAK5-SZ-3124 are hypomorphic lines that bear
two different P-element insertions in the same position of the gene,
which resides within the 59-unstranslated region (UTR) of the
mRNA. dFAK mRNA levels from whole animal RNA extract were
assessed by quantitative PCR (qPCR) using two pairs of primers:
Pair 1 (1F/1R) flanks the P-element insertion site; Pair 2 (2F/2R)
amplifies a region within the N-terminal domain spanning the
amino acid residues 120 and 188. Note all three alleles result in
very low or undetectable expression of the gene product. (C) Effect
of independent dFAK mutant allelic combinations over dRETWT-
driven rough phenotype. The three different dFAK mutant lines
were combined to produce trans-heterozygous dFAK mutants:
dFAKCG1/dFAKKG00304; GMR-dRETWT and dFAKCG1/dFAK5-SZ-3124;
GMR-dRETWT, which showed phenotype similar to dFAKCG1/
dFAKCG1; GMR-RETWT shown in Figure 1J. (D) Eye size
quantification of the indicated genotypes, corresponding to
Figure 1G, 1H, 1J, 1K, 1O and 1P. Eye size is represented as the
relative value to the wild type mean (****= p,0.0001; **= p,0.01;
‘ns’: not statistically significant; n = 8–10 for each genotype).
(PDF)
Figure S2 Src kinase and Ras act downstream of RET. (A)
Src42ARNAi or Ras85DRNAi expression in the eye with GMR-gal4
did not affect the adult eye pattern but suppressed dRETWT–
induced rough eye phenotype. (B) Src42ARNAi and Ras85DRNAi also
reduced the dRETWT-dependent suppression of Hid-induced
apoptosis, proving this anti-apoptotic role of dRET was dependent
on its effectors Src and Ras. (C) Expression of an autophospho-
rylation-site point-mutant of dFAK (dFAKY430F) produces no
defects in ommatidia patterning of the adult eye while suppressed
the severe mis-patterning caused after expression of dRETWT
within a dFAK heterozygous background, further suggesting that
the kinase activity of dFAK is not essential in this effect. Scale bars,
100 mm.
(PDF)
Figure S3 High RET/FAK ratios drive ectopic differentiation
into cone cells but not photoreceptors. (A) Immunofluorescence
stainings for the pan-neuronal marker Elav revealed that
photoreceptor differentiation was not altered in GMR-dRETWT
or dFAKCG1; GMR-dRETWT eye discs. (B) Staining for the R7-
photoreceptor marker, Prospero, at later stages of eye develop-
ment (42 h APF) showed one single R7 photoreceptor nuclei per
cluster in all genotypes. Circles indicate bristle cell nuclei, which
also express Prospero. Normally, these bristle and R7 nuclei are in
different focal planes but appear together due to misfolding in
dFAKCG1; GMR-dRETWT retinas. (C) Armadillo staining further
demonstrated the normal clusters of photoreceptor cells. All the
clusters showed seven photoreceptor cells although planar polarity
rotation problems were observed in dFAKCG1; GMR-dRETWT
retinas. (D) Ras85DRNAi expression suppressed the severely mis-
patterned and small eye phenotype of dFAKCG1; GMR-dRETWT
and 2X GMR-dRETCA flies (compare to Figure 1J and O, and 5B–
C). This suggests that Ras/MAPK signalling is the main driving
force of ectopic cone cell differentiation, which results in severe
miss patterning. (E) Cut staining of early pupa retinas (4 h APF) for
the indicated genotypes. Panels on the right show high
magnification images. Note the presence of clusters with
supernumerary cone cells in dFAKCG1; GMR-dRETWT retinas.
(PDF)
Figure S4 FAK does not regulate Src or AKT activation
downstream of RTKs. (A–F) Phosphorylated Akt immunostain-
ings, as proxy for its activation, in wing discs with the indicated
genotypes. Note Akt phosphorylation was not activated by
dRETCA or dFAK expressing tissue, or simultaneous expression
of both proteins in the ptc stripe of wing discs. In contrast, over-
expression of Drosophila Insulin Receptor (dInR) did increase pAkt
staining within the ptc stripe, but this was not reduced by dFAK co-
expression. (H–K) Independent expression of dFAK and dRETCA
caused a significant activation of Src kinase in the ptc compartment
of the wing disc, which was unchanged when both proteins were
simultaneously expressed (L). (G and L) Quantification of pAkt
and pSrc immunostaining, respectively, within the ptc stripe (see
methods). Intensity of signal is represented as relative values to the
mean intensity of control tissues overexpressing GFP and dicer2 (A
and H, respectively) (* = p,0.05; ** = p,0.01; ‘ns’: not statistically
significant; n = 4–6 for each genotype). Scale bars, 50 mm.
(PDF)
Figure S5 FAK does not suppress effects of RTK/MAPK
intermediaries Ras and Raf. The sevenless promoter driver sev-gal4
was used to map the suppression of dFAK in the RET/MAPK
pathway (GMR-gal4 resulted in pupa lethality when driving UAS-
Ras85DV12 and UAS-RafF179). dRETCA-induced patterning defects
were suppressed by dFAK co-expression, while the effects
produced by the expression of activated isoforms of Ras (RasV12)
or Raf (RafF179) were not suppressed; moreover, patches of non-
pigmented ommatidia appeared when dFAK was co-expressed,
implying that dFAK suppresses dRET signalling upstream of Ras
in the MAPK pathway.
(PDF)
Figure S6 FAK suppressed the RTK dEGFR. (A) Immuno-
staining assays showed increase phosphorylation of dFAK upon
FAK Inhibits RTK Signalling
PLOS Genetics | www.plosgenetics.org 15 March 2014 | Volume 10 | Issue 3 | e1004262
dEGFR expression in the ptc stripe of the wing disc. (B) dEGFR
did not activate Akt1 phosphorylation significantly in the ptc stripe;
dFAK co-expression made no difference either, as assessed by
quantification of immunostaining signal (B9). Scale bar, 50 mm.
Control genotypes were shown in Figure S4A–B. (C–F) Eye
micrographs show the effects of different dFAK mutant isoforms
on the dEGFR-overexpression phenotype. Note that similar to the
case of dRETCA (Figure 3), the N-terminus domain mutant
(dFAKDN) did not affect dEGFR reduced eye size, while a full-
length dFAK and a kinase mutant dFAK isoform (dFAKY430F) did
suppress this phenotype. Scale bars, 100 mm. (G) Quantification of
eye sizes from the different genotypes, expressed as relative values
to the mean value of control panel (C) (‘ns’: not statistically
significant; *** = p,0.001; **** = p,0.0001; n = 8–10 for each
genotype).
(PDF)
Figure S7 FAK negative regulation of EGFR is conserved in
MDA-MB-231 human breast adenocarcinoma cells. Expansions of
Figure 7G (A) and 7H (B), which shows the un-cropped western
blotting images for each antibody labelling. Molecular weight
markers (MM) are shown in either the first or last lanes, and the
original multicolour Li-Cor scanned images are shown in the left
panels. Expected molecular weights of proteins are: EGFR
(175 kDa); FAK (125 kDa); ERK1/2 (44/42 kDa); b-actin
(42 kDa).
(PDF)
Figure S8 Inhibition of dynamin-dependent internalisation
retains EGFR at the plasma membrane. Expansion of Figure 8D
showing the un-cropped western blotting images for each antibody
labelling. Molecular weight markers (MM) are shown in the first
lanes, and the original multicolour Li-Cor scanned images are
shown in the left panels. Expected molecular weights of proteins
are: EGFR (175 kDa); FAK (125 kDa); ERK1/2 (44/42 kDa); b-
actin (42 kDa). MDA-MB-231 cells were transfected with either
non-targeting (siNT) or FAK-specific siRNA (siFAK) and serum
starved prior to addition of 80 uM Dynasore hydrate (Sigma
Aldrich). Note that siNT-transfected cells showed an increased
phosphorylation of ERK1/2 in response to Dynasore treatment
(80 mM, 30 minutes).
(PDF)
Text S1 This text file provides a list of the full genotypes used in
all figures, as well as a list of primer sequences used for PCR.
(DOCX)
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